Capstone Therapeutics (CAPS) Expected to Announce Earnings on Tuesday

Capstone Therapeutics (NASDAQ:CAPS) is projected to post its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Capstone Therapeutics to post earnings of ($0.14) per share and revenue of $12.5130 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Capstone Therapeutics Stock Performance

Capstone Therapeutics stock traded down $0.00 during mid-day trading on Wednesday, reaching $0.70. 26,613 shares of the company traded hands, compared to its average volume of 228,095. The firm’s fifty day moving average is $0.64 and its two-hundred day moving average is $0.87. The company has a market capitalization of $6.40 million, a price-to-earnings ratio of -0.69 and a beta of -1.23. Capstone Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $3.29. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.95 and a quick ratio of 0.35.

Institutional Investors Weigh In On Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC purchased a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics at the end of the most recent quarter. 2.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Capstone Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Capstone Therapeutics currently has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.